Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Galmed initiates dosing in first-in-human phase I trial of Amilo-5MER

March 17, 2021

Pliant completes phase I study of PLN-1474 and transfers the candidate to Novartis

March 17, 2021

Phase III LUCENT-1 induction study of mirikizumab in ulcerative colitis meets endpoints

March 16, 2021

JP-1366 superior to esomeprazole for treating acid-related diseases

March 16, 2021

Fungal culprit in Crohn's disease

March 16, 2021

Novel autologous immune cell-based therapy shows promise in models of NASH

March 11, 2021

First patient dosed in phase IIa study of MET-642 for the treatment of NASH

March 10, 2021

ASC-40 reduces liver fat in phase II China cohort in NASH

March 9, 2021

Anti-inflammatory peptide amphiphiles reduce inflammation in Crohn's disease-like ileitis model

March 8, 2021

Landos reports positive phase I data for NX-13

March 5, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...